Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/dinto_DB00970
http://purl.obolibrary.org/obo/dinto_DB00970
|
|---|---|
| Preferred Name | dactinomycin |
| Synonyms |
1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
C62H86N12O16
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | dactinomycin
|
|---|---|
| label | dactinomycin
|
| DBSynonym |
dactinomicina [inn-spanish]
actinomycin c1
actinomycin d
dactinomycinum [inn-latin]
dactinomycine [inn-french]
actd
See more
See less
|
| ATCCode | L01DA01
|
| Definition | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
|
| has pharmacological target | |
| inhibits | |
| type | |
| InChIKey | InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N
|
| AHFScode | 10:00.00
|
| Synonym | 1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
C62H86N12O16
|
| xref |
ChEBI:27666
Drugs.com:http://www.drugs.com/cdi/dactinomycin.html
Wikipedia:http://en.wikipedia.org/wiki/Dactinomycin
BindingDB:50023797
RxList:http://www.rxlist.com/cgi/generic2/dactinomycin.htm
Drugs Product Database (DPD):213071
PharmGKB:PA151917012
See more
See less
|
| CASRN | 50-76-0
|
| prefixIRI | obo2:dinto_DB00970
|
| is transported by | |
| related with | |
| SMILES | [H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C
|
| may interact with | |
| InChI | InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
|
| DBBrand |
meractinomycin
cosmegen
chounghwamycin b
lyovac cosmegen
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |